Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients.
@article{Nakashita2016PossibleEO, title={Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients.}, author={Tamao Nakashita and Katsutoshi Ando and Kazuhisa Takahashi and Shinji Motojima}, journal={Respiratory investigation}, year={2016}, volume={54 5}, pages={ 376-9 } }
Rheumatoid arthritis (RA) is a generally progressive, systemic autoimmune condition characterized by chronic erosive synovitis. Interstitial lung disease (ILD) is a common extraarticular manifestation of RA and is substantially more likely to cause morbidity and mortality [1]. Several diseasemodifying anti-rheumatic drugs and numerous biological therapies for RA have been widely used. These treatments, targeted at alleviating symptoms and preventing joint destruction, represent an important… CONTINUE READING
Citations
Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS
Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
VIEW 2 EXCERPTS
CITES BACKGROUND
Lung Disease Associated with Rheumatoid Arthritis
VIEW 1 EXCERPT
CITES BACKGROUND
Comorbidity in Rheumatic Diseases
VIEW 1 EXCERPT
CITES BACKGROUND
References
Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES